[Clinical efficacy of carbapenems in the treatment of destructive pneumonia and chronic purulent bronchitis].
Sokolova
V I
VI
Russian Academy of Post-Graduate Medical Training, National Research Centre of Antibiotics, Moscow.
Shenderovich
V A
VA
Orlov
V A
VA
Smirnova
L B
LB
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D029481:Bronchitis, Chronic / Q000188:drug therapy* / Q000382:microbiology; D015780:Carbapenems / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006095:Gram-Positive Cocci / Q000187:drug effects; D006801:Humans; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D013845:Thienamycins / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D015378:Imipenem; D000077731:Meropenem